Study design

retrospective

Study time

2016.12-2019.12

Country

Netherlands

Object

Patients with biochemically recurrent, hormone-sensitive PCa, after RARP or EBRT, who underwent an 18F-DCFPyL PET/CT. Patients with rising PSA values after RARP or EBRT, and who did not meet the criteria for BCR but still underwent 18F-DCFPyL PET/CT for restaging purposes, were also included in this alysis.

Inclusion criteria

Patients who underwent primary therapy, other than RARP or EBRT (e.g., brachytherapy, focal therapy of the prostate), were excluded. Also patients who priorly underwent PSMA-based imaging for BCR with a tracer other than 18F-DCFPyL such as 68Ga-PSMA-11 or 18F-PSMA-1007 were excluded. Moreover, patients who had received adjuvant androgen deprivation therapy (ADT), any hormol therapy (HT) at the time of performing 18F-DCFPyL PET/CT, or any salvage treatment other than salvage radiation therapy (SRT) after RARP were not eligible for this alysis. 

Sample size

253

Topic classification

Other

Keypoint

A positive 18F-DCFPyL PET/CT scan, positive pathological lymph node status, and a negative surgical margin status were significantly associated with increased odds of having a change of magement based on 18F-DCFPyL PET/CT findings.

Year